Table 2.
Index admission interventions and discharge medications of early (2007–2011) and recent (2012–2017) years patients admitted with acute decompensated heart failure.
| Early (N = 4366) | Recent (N = 3966) | p-value | |
|---|---|---|---|
| Index admission interventions | |||
| Percutaneous coronary intervention | 369 (8.5) | 390 (9.8) | 0.029 |
| Coronary angiography alone | 180 (4.1) | 240 (6.1) | <0.001 |
| Pacemaker implantation | 51 (1.2) | 51 (1.3) | 0.625 |
| Cardiac resynchronization therapy | 12 (0.3) | 9 (0.2) | 0.663 |
| Coronary artery bypass grafting | 37 (0.8) | 140 (3.5) | <0.001 |
| Cardiac nuclear mapping | 0 (0.0) | 1 (0.0) | 0.294 |
| Discharge medications | |||
| Alpha blockers | 616 (14.1) | 581 (14.6) | 0.482 |
| Beta blockers | 1987 (45.5) | 2513 (63.4) | <0.001 |
| Angiotensin-converting enzyme inhibitors | 1219 (27.9) | 1114 (28.1) | 0.864 |
| Angiotensin receptor blockers | 612 (14.0) | 570 (14.4) | 0.643 |
| Aldactone | 102 (2.3) | 118 (3.0) | 0.069 |
| Calcium channel blockers | 1462 (33.5) | 1185 (29.9) | <0.001 |
| Diuretics | 3220 (73.8) | 2940 (74.1) | 0.694 |
| Digoxin | 234 (5.4) | 137 (3.5) | <0.001 |
| Statins | 2463 (56.4) | 2137 (53.9) | 0.02 |
| Other anti-hyperlipidemia drugs | 99 (2.3) | 93 (2.3) | 0.814 |
| Anti-arrhythmia drugs | 416 (9.5) | 358 (9.0) | 0.431 |
| Antiplatelets | 2781 (63.7) | 2097 (52.9) | <0.001 |
| Oral anticoagulants | 1010 (23.1) | 1144 (28.8) | <0.001 |
| Combination pills | 104 (2.4) | 137 (3.5) | 0.004 |